{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:15:20Z","timestamp":1772712920633,"version":"3.50.1"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:p>Primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) is a rare subtype of extranodal DLBCL. Because of the rarity of this disease, its morphologic and genetic features are not comprehensively studied. Here, we systematically reviewed the clinicopathologic features of 42 cases of PA-DLBCL from our institution and investigated the frequency of MYD88 L265P and CD79B (exon 5) mutation in 29 eligible cases using Sanger sequencing. Clinically, PA-DLBCL was predominant in elderly male patients with advanced clinical stage and poor outcomes. Morphologically, the tumors often showed a sinusoidal and\/or cohesive pattern with condensed chromatin and inconspicuous nucleolus which mimicked neuroendocrine carcinoma. Moreover, increased Reed-Sternberg\u2013like cells were observed frequently. These confounding morphologic manifestations may lead to misdiagnosis. Genetically, PA-DLBCL harbored a high prevalence of MYD88 L265P (24%) and CD79B mutations (52%) which may be involved in lymphomagenesis. The CD79B mutation was significantly associated with a worse prognosis. A novel Histo-Molecular Classification system (4 categories) was proposed based on correlation with genetic changes. Generally, the neuroendocrine carcinoma\u2013like type was associated with CD79B mutation, whereas the RS-like cell type indicated MYD88 L265P. The biphasic type was correlated with coexisting mutations of MYD88 and CD79B, whereas the common type implied no mutation. Furthermore, the common type showed significantly better survival. In conclusion, the proposed new category system could indicate the genetic changes as well as facilitate risk stratification to guide treatment and predict prognosis. Although this study augmented our understanding of PA-DLBCL, further analysis is required to validate our results and extend them to extranodal DLBCL at other sites.<\/jats:p>","DOI":"10.1097\/pas.0000000000001386","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T15:49:17Z","timestamp":1571068157000},"page":"444-455","source":"Crossref","is-referenced-by-count":16,"title":["Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma"],"prefix":"10.1097","volume":"44","author":[{"given":"Zihang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pujun","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunxiang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunxia","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaqi","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sha","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2019,10,11]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","article-title":"Extranodal diffuse large b cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence","volume":"19","author":"Ollila","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1007\/s00277-013-1812-3","article-title":"Primary adrenal lymphoma: a systematic review","volume":"92","author":"Rashidi","year":"2013","journal-title":"Ann Hematol"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2162-3619-2-19","article-title":"Clinicopathological analysis of primary adrenal diffuse large B-cell lymphoma: effectiveness of rituximab-containing chemotherapy including central nervous system prophylaxis","volume":"2","author":"Ichikawa","year":"2013","journal-title":"Exp Hematol Oncol"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1756-8722-5-49","article-title":"Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)","volume":"5","author":"Kim","year":"2012","journal-title":"J Hematol Oncol"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"e15662","DOI":"10.1097\/MD.0000000000015662","article-title":"Systemic and prophylactic intrathecal chemotherapy for primary adrenal lymphoma: a retrospective study of 20 case reports","volume":"98","author":"Yuan","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1177\/1066896918770022","article-title":"PAX8-positive B-cell lymphoma in adrenal gland masquerading as metastatic renal cell carcinoma","volume":"26","author":"Parakh","year":"2018","journal-title":"Int J Surg Pathol"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00428-018-2378-1","article-title":"Primary adrenal diffuse large B cell lymphoma: a clinicopathological and molecular study from China","volume":"473","author":"Zhang","year":"2018","journal-title":"Virchows Arch"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1097\/PAS.0000000000000836","article-title":"Anaplastic variant of diffuse large B-cell lymphoma displays intricate genetic alterations and distinct biological features","volume":"41","author":"Li","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/PAS.0000000000000592","article-title":"Frequent MYD88 L265P and CD79B mutations in primary breast diffuse large B-cell lymphoma","volume":"40","author":"Taniguchi","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/neup.12405","article-title":"Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma","volume":"37","author":"Zheng","year":"2017","journal-title":"Neuropathology"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00401-012-1064-7","article-title":"Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma","volume":"124","author":"Montesinos-Rongen","year":"2012","journal-title":"Acta Neuropathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1038\/bcj.2013.28","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites","volume":"3","author":"Kraan","year":"2013","journal-title":"Blood Cancer J"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/leu.2013.348","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma","volume":"28","author":"Kraan","year":"2014","journal-title":"Leukemia"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1182\/blood-2017-12-822817","article-title":"High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma","volume":"131","author":"AMR","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"R16-20230922","first-page":"4000","article-title":"High prevalence of oncogenic MYD88 and CD79B mutations in intravascular large B-cell lymphoma: implication for therapy with Bruton\u2019s kinase inhibitors?","volume":"130","author":"Somers","year":"2017","journal-title":"Blood"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1080\/10428190310001615756","article-title":"Adrenal involvement in non-Hodgkin\u2019s lymphoma: four cases and review of literature","volume":"45","author":"Singh","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/01.rlu.0000155983.46815.1c","article-title":"FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature","volume":"30","author":"Kumar","year":"2005","journal-title":"Clin Nucl Med"},{"key":"R19-20230922","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1007\/s00277-019-03740-9","article-title":"Clinical characteristics and outcomes of primary adrenal diffuse large B cell lymphoma in a large contemporary cohort: a SEER-based analysis","volume":"98","author":"Li","year":"2019","journal-title":"Ann Hematol"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/modpathol.2009.87","article-title":"Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis","volume":"22","author":"Mozos","year":"2009","journal-title":"Mod Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.1102","article-title":"Systemic anaplastic large-cell lymphoma: results from the non-Hodgkin\u2019s lymphoma classification project","volume":"67","author":"Weisenburger","year":"2001","journal-title":"Am J Hematol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"6051","DOI":"10.1002\/cam4.1875","article-title":"Clinicopathological analysis of primary intestinal diffuse large B-cell lymphoma: prognostic evaluation of CD5, PD-L1, and Epstein-Barr virus on tumor cells","volume":"7","author":"Ishikawa","year":"2018","journal-title":"Cancer Med"},{"key":"R23-20230922","first-page":"507","article-title":"Diffuse large B-cell lymphoma showing CNS invasion by CD30-positive multinuclear giant cells mimicking the clinical features of progressive multifocal leukoencephalopathy","volume":"41","author":"Ando","year":"2000","journal-title":"Rinsho Ketsueki"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/DAD.0b013e3181eeb433","article-title":"The histomorphologic spectrum of primary cutaneous diffuse large B-cell lymphoma: a study of 79 cases","volume":"33","author":"Plaza","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"R25-20230922","first-page":"1481","article-title":"Primary diffuse large B-cell lymphoma of the heart: a clinicopathological study","volume":"26","author":"Wu","year":"2006","journal-title":"Nan Fang Yi Ke Da Xue Xue Bao"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically active MYD88 mutations in human lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"R27-20230922","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nature08638","article-title":"Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma","volume":"463","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/gcc.22126","article-title":"Targetable activating mutations are very frequent in GCB and ABC diffuse large B-cell lymphoma","volume":"53","author":"Bohers","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"R29-20230922","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.05.008","article-title":"Mutations of the B-cell receptor pathway confer chemoresistance in primary cutaneous diffuse large B-cell lymphoma leg-type","author":"Ducharme","year":"2019","journal-title":"J Invest Dermatol"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/pin.12439","article-title":"Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P","volume":"66","author":"Nagakita","year":"2016","journal-title":"Pathol Int"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1080\/10428194.2017.1370546","article-title":"Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL","volume":"59","author":"Frick","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"102888","DOI":"10.18632\/oncotarget.21986","article-title":"Mutational profile of primary breast diffuse large B-cell lymphoma","volume":"8","author":"Franco","year":"2017","journal-title":"Oncotarget"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s00277-017-3094-7","article-title":"Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations","volume":"96","author":"Cao","year":"2017","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"R34-20230922","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1182\/blood-2018-99-114551","article-title":"Primary extranodal diffuse large B-cell lymphomas are enriched for mutations in MYD88 and CD79B","volume":"132","author":"Weissinger","year":"2018","journal-title":"Blood"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jid.2018.04.038","article-title":"Genomic analyses identify recurrent alterations in immune evasion genes in diffuse large B-cell lymphoma, Leg type","volume":"138","author":"Zhou","year":"2018","journal-title":"J Invest Dermatol"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/j.jid.2017.04.010","article-title":"Identification of somatic mutations in primary cutaneous diffuse large B-cell lymphoma, Leg type by massive parallel sequencing","volume":"137","author":"Mareschal","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"R38-20230922","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1038\/s41598-017-01998-5","article-title":"Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis","volume":"7","author":"Lee","year":"2017","journal-title":"Sci Rep"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1158\/1078-0432.CCR-16-1922","article-title":"Biological and clinical relevance of associated genomic alterations in MYD88 L265P and non-L265P-mutated diffuse large B-cell lymphoma: analysis of 361 cases","volume":"23","author":"Dubois","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.13191","article-title":"CD79B mutations in primary vitreoretinal lymphoma: diagnostic and prognostic potential","volume":"102","author":"Yonese","year":"2019","journal-title":"Eur J Haematol"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/nchembio.502","article-title":"Drug discovery: new Btk inhibitor holds promise","volume":"7","author":"Hendriks","year":"2011","journal-title":"Nat Chem Biol"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N Engl J Med"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.ccell.2017.04.012","article-title":"Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma","volume":"31","author":"Lionakis","year":"2017","journal-title":"Cancer Cell"},{"key":"R44-20230922","first-page":"6203","article-title":"MYD88 Inhibitor ST2825 suppresses the growth of lymphoma and leukaemia cells","volume":"37","author":"Shiratori","year":"2017","journal-title":"Anticancer Res"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1158\/0008-5472.CAN-10-2525","article-title":"Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas","volume":"71","author":"Naylor","year":"2011","journal-title":"Cancer Res"},{"key":"R46-20230922","doi-asserted-by":"crossref","first-page":"24","DOI":"10.4103\/IJPM.IJPM_516_16","article-title":"Epidermal growth factor receptor and anaplastic lymphoma kinase mutation in adenocarcinoma lung: their incidence and correlation with histologic patterns","volume":"62","author":"Gupta","year":"2019","journal-title":"Indian J Pathol Microbiol"},{"key":"R47-20230922","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2008.04.017","article-title":"Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type","volume":"63","author":"Ninomiya","year":"2009","journal-title":"Lung Cancer"},{"key":"R48-20230922","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.leukres.2018.10.017","article-title":"The predictive value of morphological findings in early diagnosis of acute myeloid leukemia with recurrent cytogenetic abnormalities","volume":"75","author":"Jakovic","year":"2018","journal-title":"Leuk Res"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3324\/haematol.12810","article-title":"De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients","volume":"93","author":"Yamaguchi","year":"2008","journal-title":"Haematologica"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001386","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:58:39Z","timestamp":1695423519000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,11]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001386","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,11]]}}}